Evidence map›Paper›PMID 41816577›Full record

ArticleJournal of gastrointestinal oncology2026

Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer.

Anita Archwamety, Charuwan Akewanlop, Krittiya Korphaisarn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Anita ArchwametyDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Charuwan AkewanlopDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Krittiya KorphaisarnDivision of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID https://orcid.org/0000-0001-5739-0175

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) are the standard first-line treatment in Methods: We conducted a retrospective study in patients diagnosed with Results: Of 300 patients with Conclusions: While earlier line use confers longer PFS, OS remains similar regardless of the timing of anti-EGFR therapy. These findings support the introduction of anti-EGFR agents at any line when feasible, highlighting that ensuring access may be more important than timing in treatment sequencing.

Indexed as

anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb)Colorectal cancer (CRC)left-sided colon cancerRAS wild-type (RASwt)

Identifiers

PMID41816577
PMCPMC12971999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.